First-in-class small molecule drug discovery of renin/ prorenin receptor blockers (RERBs)

In cooperation with the contract research organizations Evotec AG and Experimental Pharmacology & Oncology (EPO) GmbH, the company develops small molecule renin/ prorenin receptor blockers (RERBs) for the following indications:

(1) multiple oncologic malignancies (e.g. colorectal cancer, pancreatic cancer, hepatocellular carcinoma, sarcoma)

(2) end-organ damage caused by diabetes and hypertension (diabetic nephropathy, diabetic retinopathy, heart failure)

Current status

(1) oncology: start preclinical development

(2) cardiorenal: within lead optimization